Jeil Pharmaceutical Co.,Ltd (KRX:271980)
South Korea · Delayed Price · Currency is KRW 10,100
-60 (-0.59%)
Sep 11, 2026, 3:30 PM KST
KRX:271980 Revenue
Jeil Pharmaceutical Co.,Ltd had revenue of 146.60B KRW in the quarter ending June 30, 2026, with 6.52% growth. This brings the company's revenue in the last twelve months to 543.49B, down -17.85% year-over-year. In the year 2025, Jeil Pharmaceutical Co.,Ltd had annual revenue of 567.24B, down -19.49%.
Revenue (ttm)
543.49B
Revenue Growth
-17.85%
P/S Ratio
0.27
Revenue / Employee
573.91M
Employees
947
Market Cap
147.17B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 567.24B | -137.30B | -19.49% |
| Dec 31, 2024 | 704.54B | -21.85B | -3.01% |
| Dec 31, 2023 | 726.39B | 4.16B | 0.58% |
| Dec 31, 2022 | 722.23B | 21.54B | 3.07% |
| Dec 31, 2021 | 700.69B | 9.37B | 1.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Daewon Pharmaceutical | 614.64B |
| Dongwha Pharm.Co.,Ltd | 513.24B |
| Kyongbo Pharmaceutical | 279.55B |
| Ilyang Pharmaceutical Co.,Ltd | 277.96B |
| JW Lifescience | 253.71B |
| Daihan Pharmaceutical | 216.55B |
| Samil Pharmaceutical Co.,Ltd | 207.33B |
| Hana Pharm | 139.33B |